Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab Clinical Trials in Boston, Massachusetts

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors